ES2387292B1 - Combinacion de snps para determinar el riesgo de sufrir una enfermedad neurovascular - Google Patents
Combinacion de snps para determinar el riesgo de sufrir una enfermedad neurovascular Download PDFInfo
- Publication number
- ES2387292B1 ES2387292B1 ES201031004A ES201031004A ES2387292B1 ES 2387292 B1 ES2387292 B1 ES 2387292B1 ES 201031004 A ES201031004 A ES 201031004A ES 201031004 A ES201031004 A ES 201031004A ES 2387292 B1 ES2387292 B1 ES 2387292B1
- Authority
- ES
- Spain
- Prior art keywords
- snps
- combination
- individual
- neurovascular
- stroke
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn - After Issue
Links
- 208000017376 neurovascular disease Diseases 0.000 title claims abstract description 92
- 238000000034 method Methods 0.000 claims abstract description 46
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 33
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 33
- 239000002157 polynucleotide Substances 0.000 claims abstract description 33
- 102200101327 rs5742912 Human genes 0.000 claims abstract description 32
- 239000002773 nucleotide Substances 0.000 claims abstract description 25
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 25
- 238000001514 detection method Methods 0.000 claims abstract description 17
- 102000054765 polymorphisms of proteins Human genes 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 73
- 108700028369 Alleles Proteins 0.000 claims description 57
- 230000002068 genetic effect Effects 0.000 claims description 39
- 230000000694 effects Effects 0.000 claims description 27
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 239000000523 sample Substances 0.000 claims description 24
- 206010020772 Hypertension Diseases 0.000 claims description 23
- 101000577881 Homo sapiens Macrophage metalloelastase Proteins 0.000 claims description 22
- 101001124309 Homo sapiens Nitric oxide synthase, endothelial Proteins 0.000 claims description 22
- 101001128156 Homo sapiens Nanos homolog 3 Proteins 0.000 claims description 21
- 102100027998 Macrophage metalloelastase Human genes 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 21
- 206010012601 diabetes mellitus Diseases 0.000 claims description 19
- 230000014509 gene expression Effects 0.000 claims description 19
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 238000012360 testing method Methods 0.000 claims description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 230000000391 smoking effect Effects 0.000 claims description 14
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 claims description 13
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 claims description 13
- 102100037242 Amiloride-sensitive sodium channel subunit alpha Human genes 0.000 claims description 11
- 101001039256 Caenorhabditis elegans Low-density lipoprotein receptor-related protein Proteins 0.000 claims description 11
- 101000694288 Homo sapiens 40S ribosomal protein SA Proteins 0.000 claims description 11
- 101000740448 Homo sapiens Amiloride-sensitive sodium channel subunit alpha Proteins 0.000 claims description 11
- 101001030069 Homo sapiens Major vault protein Proteins 0.000 claims description 11
- 101000974732 Homo sapiens Potassium channel subfamily K member 17 Proteins 0.000 claims description 11
- 101000738769 Homo sapiens Receptor-type tyrosine-protein phosphatase alpha Proteins 0.000 claims description 11
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 10
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 10
- 102100022757 Potassium channel subfamily K member 17 Human genes 0.000 claims description 9
- 108020004414 DNA Proteins 0.000 claims description 7
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 claims description 7
- 108091034117 Oligonucleotide Proteins 0.000 claims description 7
- 102220471347 Cadherin EGF LAG seven-pass G-type receptor 1_I2107V_mutation Human genes 0.000 claims description 5
- 102220471349 Cadherin EGF LAG seven-pass G-type receptor 1_T2268A_mutation Human genes 0.000 claims description 5
- 102220527215 Hypoxia-inducible factor 1-alpha inhibitor_P41A_mutation Human genes 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 5
- 102210011514 rs2200733 Human genes 0.000 claims description 5
- 102210008969 rs7193343 Human genes 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 230000002285 radioactive effect Effects 0.000 claims description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 238000009396 hybridization Methods 0.000 claims description 2
- 239000002853 nucleic acid probe Substances 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 description 109
- 208000032382 Ischaemic stroke Diseases 0.000 description 27
- 210000000349 chromosome Anatomy 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 14
- 108020004999 messenger RNA Proteins 0.000 description 14
- 239000008280 blood Substances 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 238000012937 correction Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 102100022278 Arachidonate 5-lipoxygenase-activating protein Human genes 0.000 description 4
- 206010019013 Haemorrhagic infarction Diseases 0.000 description 4
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 4
- 101000755875 Homo sapiens Arachidonate 5-lipoxygenase-activating protein Proteins 0.000 description 4
- 101000587058 Homo sapiens Methylenetetrahydrofolate reductase Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 101150077458 KCNK17 gene Proteins 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 4
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 238000003205 genotyping method Methods 0.000 description 4
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 101150082646 scnn1a gene Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 3
- 101001064864 Homo sapiens Polyunsaturated fatty acid lipoxygenase ALOX12 Proteins 0.000 description 3
- 101001049841 Homo sapiens Potassium channel subfamily K member 1 Proteins 0.000 description 3
- 101000799466 Homo sapiens Thrombopoietin receptor Proteins 0.000 description 3
- 101000744900 Homo sapiens Zinc finger homeobox protein 3 Proteins 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 102100032999 Integrin beta-3 Human genes 0.000 description 3
- 102100029684 Methylenetetrahydrofolate reductase Human genes 0.000 description 3
- 101150101095 Mmp12 gene Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 102100031949 Polyunsaturated fatty acid lipoxygenase ALOX12 Human genes 0.000 description 3
- 102100023242 Potassium channel subfamily K member 1 Human genes 0.000 description 3
- 102000018674 Sodium Channels Human genes 0.000 description 3
- 108010052164 Sodium Channels Proteins 0.000 description 3
- 102100034196 Thrombopoietin receptor Human genes 0.000 description 3
- 102100039966 Zinc finger homeobox protein 3 Human genes 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 102100029170 cAMP-specific 3',5'-cyclic phosphodiesterase 4D Human genes 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- -1 cyclic amino acid Chemical class 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000020764 fibrinolysis Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 3
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000012954 risk control Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 201000009032 substance abuse Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- AQQSXKSWTNWXKR-UHFFFAOYSA-N 2-(2-phenylphenanthro[9,10-d]imidazol-3-yl)acetic acid Chemical compound C1(=CC=CC=C1)C1=NC2=C(N1CC(=O)O)C1=CC=CC=C1C=1C=CC=CC=12 AQQSXKSWTNWXKR-UHFFFAOYSA-N 0.000 description 2
- 101150101112 7 gene Proteins 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 2
- 206010059245 Angiopathy Diseases 0.000 description 2
- 102100029470 Apolipoprotein E Human genes 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-M Arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O YZXBAPSDXZZRGB-DOFZRALJSA-M 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 244000186140 Asperula odorata Species 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 208000010482 CADASIL Diseases 0.000 description 2
- 208000033221 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 description 2
- 208000033935 Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 108010072220 Cyclophilin A Proteins 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101150104463 GOS2 gene Proteins 0.000 description 2
- 235000008526 Galium odoratum Nutrition 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 206010018852 Haematoma Diseases 0.000 description 2
- 101000896414 Homo sapiens Nuclear nucleic acid-binding protein C1D Proteins 0.000 description 2
- 101001067833 Homo sapiens Peptidyl-prolyl cis-trans isomerase A Proteins 0.000 description 2
- 101001123846 Homo sapiens Serine/threonine-protein kinase Nek1 Proteins 0.000 description 2
- 101000759879 Homo sapiens Tetraspanin-10 Proteins 0.000 description 2
- 101000988419 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4D Proteins 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000034800 Leukoencephalopathies Diseases 0.000 description 2
- 208000035177 MELAS Diseases 0.000 description 2
- 101150117253 NINJ2 gene Proteins 0.000 description 2
- 102100027889 Ninjurin-2 Human genes 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 2
- 108010029756 Notch3 Receptor Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102100036090 Pituitary homeobox 2 Human genes 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 102100028751 Serine/threonine-protein kinase Nek1 Human genes 0.000 description 2
- 108700012920 TNF Proteins 0.000 description 2
- 102100024990 Tetraspanin-10 Human genes 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 2
- 229960002576 amiloride Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 229940114078 arachidonate Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 206010061592 cardiac fibrillation Diseases 0.000 description 2
- 230000009426 cardioembolic effect Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 208000016886 cerebral arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000002600 fibrillogenic effect Effects 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 101150084157 lrp-1 gene Proteins 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 230000000276 sedentary effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 230000002739 subcortical effect Effects 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 101150098072 20 gene Proteins 0.000 description 1
- 101710188260 5,10-methylenetetrahydrofolate reductase Proteins 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102100037232 Amiloride-sensitive sodium channel subunit beta Human genes 0.000 description 1
- 102100022534 Amiloride-sensitive sodium channel subunit gamma Human genes 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- 102000011730 Arachidonate 12-Lipoxygenase Human genes 0.000 description 1
- 108010076676 Arachidonate 12-lipoxygenase Proteins 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 102100028668 C-type lectin domain family 4 member C Human genes 0.000 description 1
- 229940126074 CDK kinase inhibitor Drugs 0.000 description 1
- 102100025659 Cadherin EGF LAG seven-pass G-type receptor 1 Human genes 0.000 description 1
- 101710146248 Cadherin EGF LAG seven-pass G-type receptor 1 Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000021910 Cerebral Arterial disease Diseases 0.000 description 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 1
- 108010077773 Complement C4a Proteins 0.000 description 1
- 108010077762 Complement C4b Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 1
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000003837 Epithelial Sodium Channels Human genes 0.000 description 1
- 108090000140 Epithelial Sodium Channels Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 240000008168 Ficus benjamina Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000740426 Homo sapiens Amiloride-sensitive sodium channel subunit beta Proteins 0.000 description 1
- 101000822373 Homo sapiens Amiloride-sensitive sodium channel subunit gamma Proteins 0.000 description 1
- 101000766907 Homo sapiens C-type lectin domain family 4 member C Proteins 0.000 description 1
- 101000914155 Homo sapiens Cadherin EGF LAG seven-pass G-type receptor 1 Proteins 0.000 description 1
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 101000632159 Homo sapiens Ninjurin-2 Proteins 0.000 description 1
- 101000595669 Homo sapiens Pituitary homeobox 2 Proteins 0.000 description 1
- 206010020365 Homocystinuria Diseases 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021024 Hypolipidaemia Diseases 0.000 description 1
- 108010020950 Integrin beta3 Proteins 0.000 description 1
- 102000008607 Integrin beta3 Human genes 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 208000004552 Lacunar Stroke Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108010061306 Lipoprotein Receptors Proteins 0.000 description 1
- 102000011965 Lipoprotein Receptors Human genes 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 108010076501 Matrix Metalloproteinase 12 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100025247 Neurogenic locus notch homolog protein 3 Human genes 0.000 description 1
- 101710091555 Ninjurin-2 Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 241000426956 Pelagia Species 0.000 description 1
- 101710106040 Pituitary homeobox 2 Proteins 0.000 description 1
- 102100021556 Protein kinase C eta type Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 101100006979 Rattus norvegicus C4 gene Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010043647 Thrombotic Stroke Diseases 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 208000005386 Transient Global Amnesia Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 208000009443 Vascular Malformations Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000005744 arteriovenous malformation Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000007816 calorimetric assay Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000007213 cerebrovascular event Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003541 chymotrypsin inhibitor Substances 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000000092 effect on stroke Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000008487 fibromuscular dysplasia Diseases 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 210000003783 haploid cell Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 101150000411 lrp gene Proteins 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 201000003694 methylmalonic acidemia Diseases 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000037420 neurological improvement Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 238000003068 pathway analysis Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 108010027883 protein kinase C eta Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000010967 transthoracic echocardiography Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201031004A ES2387292B1 (es) | 2010-06-29 | 2010-06-29 | Combinacion de snps para determinar el riesgo de sufrir una enfermedad neurovascular |
| PCT/IB2011/052818 WO2012001613A1 (fr) | 2010-06-29 | 2011-06-27 | Combinaison de six snp destinée à la détection de la prédisposition pour des maladies neurovasculaires |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201031004A ES2387292B1 (es) | 2010-06-29 | 2010-06-29 | Combinacion de snps para determinar el riesgo de sufrir una enfermedad neurovascular |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2387292A1 ES2387292A1 (es) | 2012-09-19 |
| ES2387292B1 true ES2387292B1 (es) | 2013-10-30 |
Family
ID=44511771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES201031004A Withdrawn - After Issue ES2387292B1 (es) | 2010-06-29 | 2010-06-29 | Combinacion de snps para determinar el riesgo de sufrir una enfermedad neurovascular |
Country Status (2)
| Country | Link |
|---|---|
| ES (1) | ES2387292B1 (fr) |
| WO (1) | WO2012001613A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108504741A (zh) * | 2018-05-29 | 2018-09-07 | 成都中创清科医学检验所有限公司 | 一种用于检测卵巢癌基因多态性位点的引物及其检测方法 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2981617B1 (fr) | 2013-04-04 | 2023-07-05 | President and Fellows of Harvard College | Utilisations thérapeutiques de l'édition de génome au moyen de systèmes crispr/cas |
| EP2843056B8 (fr) * | 2013-08-30 | 2019-06-26 | GENINCODE UK, Ltd. | Marqueurs de risque de maladie cardiovasculaire chez des patients atteints de maladie rénale chronique |
| EP2873738A1 (fr) | 2013-11-15 | 2015-05-20 | Latvian Biomedical Research and Study Centre | Composition SNP et procédé permettant de diagnostiquer un risque de dyslipidémie |
| AU2014407088B2 (en) | 2014-09-26 | 2021-09-23 | Somalogic Operating Co., Inc. | Cardiovascular risk event prediction and uses thereof |
| KR101572165B1 (ko) | 2014-12-09 | 2015-11-26 | 삼성전자 주식회사 | 디스플레이 장치 및 이에 포함되는 백 라이트 유닛 |
| BR112017020750A2 (pt) | 2015-03-27 | 2018-06-26 | Harvard College | células t modificadas e métodos de produção e utilização das mesmas |
| US11913015B2 (en) | 2017-04-17 | 2024-02-27 | University Of Maryland, College Park | Embryonic cell cultures and methods of using the same |
| WO2023205243A1 (fr) * | 2022-04-19 | 2023-10-26 | The Regents Of The University Of Michigan | Détermination du risque de dysplasie fibromusculaire et systèmes et procédés d'utilisation associés |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005083127A2 (fr) * | 2004-02-27 | 2005-09-09 | Applera Corporation | Polymorphismes genetiques associes a l'accident vasculaire cerebral, methodes de detection et utilisations correspondantes |
| WO2007086980A2 (fr) * | 2005-11-10 | 2007-08-02 | Duke University | Méthodes permettant de déterminer le risque de développer une coronaropathie |
| EP2129795A4 (fr) * | 2006-12-19 | 2010-10-20 | Synergenz Bioscience Ltd | Procédés et compositions pour l'évaluation de la fonction et de troubles cardiovasculaires |
| KR101019952B1 (ko) * | 2008-05-27 | 2011-03-11 | 박민구 | 뇌졸중 조기진단 칩 그리고 이를 이용한 뇌졸중 스크리닝검사 |
-
2010
- 2010-06-29 ES ES201031004A patent/ES2387292B1/es not_active Withdrawn - After Issue
-
2011
- 2011-06-27 WO PCT/IB2011/052818 patent/WO2012001613A1/fr not_active Ceased
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108504741A (zh) * | 2018-05-29 | 2018-09-07 | 成都中创清科医学检验所有限公司 | 一种用于检测卵巢癌基因多态性位点的引物及其检测方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012001613A1 (fr) | 2012-01-05 |
| ES2387292A1 (es) | 2012-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2387292B1 (es) | Combinacion de snps para determinar el riesgo de sufrir una enfermedad neurovascular | |
| Haram et al. | Genetic aspects of preeclampsia and the HELLP syndrome | |
| Cusi et al. | Polymorphisms of α-adducin and salt sensitivity in patients with essential hypertension | |
| CN110684838A (zh) | 一种肥厚型心肌病基因检测试剂盒 | |
| Huang et al. | Genetic polymorphisms of the renin-angiotensin-aldosterone system in Chinese patients with end-stage renal disease secondary to IgA nephropathy | |
| Yamada et al. | Identification of six polymorphisms as novel susceptibility loci for ischemic or hemorrhagic stroke by exome-wide association studies | |
| Nishigaki et al. | Mitochondrial haplogroup A is a genetic risk factor for atherothrombotic cerebral infarction in Japanese females | |
| Conte et al. | A genome search for primary vesicoureteral reflux shows further evidence for genetic heterogeneity | |
| Alkelai et al. | Identification of new schizophrenia susceptibility loci in an ethnically homogeneous, family‐based, Arab‐Israeli sample | |
| CN110656112A (zh) | 一种Liddle综合征基因检测试剂盒 | |
| Zizzo et al. | Systematic DNA study for Fabry disease in the end stage renal disease patients from a southern Italy area | |
| Hasi et al. | Acetaldehyde dehydrogenase 2 SNP rs671 and susceptibility to essential hypertension in Mongolians: a case control study | |
| Domingues-Montanari et al. | KCNK17 genetic variants in ischemic stroke | |
| Li et al. | Genome-wide association study of high-altitude pulmonary edema in a Han Chinese population | |
| Lee et al. | Association between a polymorphism in CASP3 and CASP9 genes and ischemic stroke | |
| Droma et al. | Two hypoxia sensor genes and their association with symptoms of acute mountain sickness in Sherpas | |
| Dewi et al. | Association polymorphism of guanine nucleotide–binding protein β3 subunit (GNB3) C825T and insertion/deletion of the angiotensin-converting enzyme (ACE) gene with peripartum cardiomyopathy | |
| Pitha et al. | Genetic determination of the prognosis in survivors of acute coronary syndromes. Study design and rationale for a multicenter study | |
| Gaber et al. | The significance of PCSK-9′ s level and polymorphism in premature coronary artery disease: Relation to risk and severity | |
| CN108753945A (zh) | 与中国儿童肥胖和/或高三酰甘油血症相关的snp位点及其应用 | |
| Wu et al. | A meta-analysis of PDE-gene polymorphism and cerebral infarction risk | |
| Li et al. | Analysis of CYP2C19 gene genotype in patients with acute cerebral infarction and its relationship with disease progression | |
| WO2014173986A2 (fr) | Procédés pour diagnostiquer et surveiller la réponse à un traitement de carcinome hépatocellulaire | |
| Rizvi et al. | Association of NOS3 (rs1799983) and DDAH2 (rs805305) Gene Polymorphisms With Coronary Artery Disease in the Northern Indian Cohort | |
| Purkait et al. | Renin-angiotensin-aldosterone system gene polymorphisms in Type 2 diabetic patients among the Mewari population of Rajasthan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 2387292 Country of ref document: ES Kind code of ref document: B1 Effective date: 20131030 |
|
| FA2A | Application withdrawn |
Effective date: 20140226 |